161 related articles for article (PubMed ID: 35016731)
21. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.
Bayle M; Clerc-Urmès I; Ayav A; Bronowicki JP; Petit I; Orry X; Laurent V
Abdom Radiol (NY); 2019 Jan; 44(1):85-94. PubMed ID: 30054686
[TBL] [Abstract][Full Text] [Related]
22. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
23. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome.
Herber S; Biesterfeld S; Franz U; Schneider J; Thies J; Schuchmann M; Düber C; Pitton MB; Otto G
Cardiovasc Intervent Radiol; 2008; 31(4):768-77. PubMed ID: 18196335
[TBL] [Abstract][Full Text] [Related]
24. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
25. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
26. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
27. Role of surgical resection for multiple hepatocellular carcinomas.
Choi SH; Choi GH; Kim SU; Park JY; Joo DJ; Ju MK; Kim MS; Choi JS; Han KH; Kim SI
World J Gastroenterol; 2013 Jan; 19(3):366-74. PubMed ID: 23372359
[TBL] [Abstract][Full Text] [Related]
28. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation.
Cascales-Campos PA; Ramírez P; Lopez V; Gonzalez R; Saenz-Mateos L; Llacer E; Sánchez Bueno F; Robles R; Pons JA; Capel A; Frutos L; Navarro JL; Muñoz-Ramon P; Parrilla P
Transplant Proc; 2015 Oct; 47(8):2374-6. PubMed ID: 26518931
[TBL] [Abstract][Full Text] [Related]
30. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
[TBL] [Abstract][Full Text] [Related]
31. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization.
Bryant MK; Dorn DP; Zarzour J; Smith JK; Redden DT; Saddekni S; Abdel Aal AK; Gray SH; Eckhoff DE; Dubay DA
HPB (Oxford); 2014 Apr; 16(4):327-35. PubMed ID: 23980917
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
[TBL] [Abstract][Full Text] [Related]
33. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
34. Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma.
Young S; Sanghvi T; Sharma S; Richardson C; Rubin N; Richards M; D'Souza D; Flanagan S; Golzarian J
Diagn Interv Imaging; 2022 Mar; 103(3):143-149. PubMed ID: 35115276
[TBL] [Abstract][Full Text] [Related]
35. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
[TBL] [Abstract][Full Text] [Related]
36. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.
Sacco R; Bertini M; Petruzzi P; Bertoni M; Bargellini I; Bresci G; Federici G; Gambardella L; Metrangolo S; Parisi G; Romano A; Scaramuzzino A; Tumino E; Silvestri A; Altomare E; Vignali C; Capria A
World J Gastroenterol; 2009 Apr; 15(15):1843-8. PubMed ID: 19370781
[TBL] [Abstract][Full Text] [Related]
38. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
39. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
Kaufmann S; Schulze M; Spira D; Horger M
Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
[TBL] [Abstract][Full Text] [Related]
40. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone.
Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Artzner C; Bitzer M; Horger M; Grözinger G
Eur J Radiol; 2021 Jul; 140():109768. PubMed ID: 33991970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
